

## Press Release

### **Ajanta signs in-licensing agreement with Biocon for marketing Semaglutide in 26 countries**

**Mumbai, 23<sup>rd</sup> December 2025:** Ajanta Pharma Ltd., a specialty pharmaceutical formulation company, today announced that it has entered into an in-licensing agreement with Biocon Ltd. for Semaglutide, a GLP-1 receptor agonist.

Under the agreement, Biocon will supply Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, the Middle East and Central Asia.

Semaglutide, the GLP-1 receptor agonist, is to improve glycaemic control in adults. The product patent expires in most of these markets in March 2026. Ajanta plans to commercialize the products after receiving the regulatory approvals, which are expected in late 2026 or early 2027.

Ajanta has been one of the pioneers among Indian companies to build a strong branded generic business with own field force in over 30 countries across Africa, South-East Asia, Central Asia and the Middle East. In these markets, company has presence in a wide range of therapeutic segments like, Cardiology, Antidiabetic, Ophthalmology, Antibiotic, Antimalarial, Pain, Gynaecology, Paediatric and General Health products.

Over the years, Ajanta has strengthened its presence in these markets by expanding its product portfolio, growing its field size and building leadership positions across several therapeutic and sub-therapeutic segments. Today it has more than 220 brands in emerging markets with many holding leadership positions in their therapeutic and sub-therapeutic segments. These brands are well established and renowned in the international medical fraternity with over 2,000 MRs marketing these products on the ground.

Ajanta's key strength is its ability to identify gaps in marketplace, obtain the regulatory approvals for new products and launch differentiated products that scale into strong, sustainable brands. The company has a robust product pipeline under regulatory approval, which is expected to further strengthen its leadership across key therapeutic segments.

Commenting on the agreement, Yogesh Agrawal, Managing Director, Ajanta Pharma Ltd., said, "GLP-1 therapies have seen rapid global acceptance and have emerged as blockbuster products worldwide. We are excited to partner with Biocon for Semaglutide and take this important therapy to the markets where Ajanta has strong on-ground presence and deep reach. We are confident of building Semaglutide into a meaningful and high-growth brand across these countries in the years ahead."

On the collaboration, Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Ltd., said, "This partnership with Ajanta Pharma is a strategic step in expanding the global footprint of Biocon's GLP-1 portfolio and maximizing the value of our scientific investments in complex peptide development. Semaglutide represents a significant advancement in diabetes care, and Ajanta's deep commercial reach across Africa, the Middle East and Central Asia provides an efficient and scalable pathway to accelerate market access. Importantly, this collaboration will enable broader and more affordable access to Semaglutide for patients in these regions, supporting our commitment to improving health outcomes through high-quality, cost-effective medicines."

## **About Ajanta Pharma Limited**

Ajanta Pharma is a specialty pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa. It has ground presence in each of these 30+ countries. Many of Ajanta's products are 1st to market and are leading in their sub-therapeutic segments. The company also has presence in USA in generic business and institution business in Africa.

Ajanta has its state-of-the-art R&D centre in Mumbai. The company has 7 world class manufacturing facilities located in India.

For the FY 2024-25, Ajanta has posted the Revenue of Rs. 4,648 cr., EBIDTA of Rs. 1,260 cr. (27%) and PAT of Rs. 920 cr. (20%). For the last 3 financial years, Ajanta has posted healthy revenue CAGR of 11% and even stronger PAT CAGR of 25%.

For more details visit [www.ajantapharma.com](http://www.ajantapharma.com)

## **About Biocon Limited**

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led, global biopharmaceutical company committed to enhancing affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. [www.biocon.com](http://www.biocon.com)

### **For media queries, contact:**

Abhineet Kumar Tel: +91 22 6060 9721 Email: [abhineet.kumar@ajantapharma.com](mailto:abhineet.kumar@ajantapharma.com)

### **For investor related queries, contact:**

Rajeev Agarwal Tel: +91 22 6060 9706 Email: [rajeev.agarwal@ajantapharma.com](mailto:rajeev.agarwal@ajantapharma.com)

For regular updates follow us on x.com – <https://x.com/AjantaPharmaLtd>

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331

### **Safe Harbour Statement**